Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT) and Capricor Therapeutics (NASDAQ: CAPR)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PTC Therapeutics (NASDAQ: PTCT) and Capricor Therapeutics (NASDAQ: CAPR).

PTC Therapeutics (NASDAQ: PTCT)

Cowen & Co. analyst Ritu Baral reiterated a Hold rating on PTC Therapeutics (NASDAQ: PTCT) today. The company’s shares opened today at $10.09.

Baral observed:

“PTCT announced 4Q16 results today: Translarna EU sales continue to grow.”

According to TipRanks.com, Baral is a 5-star analyst with an average return of 9.5% and a 43.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on PTC Therapeutics is Hold and the average price target is $12, representing a 18.9% upside.

In a report issued on March 3, Barclays also downgraded the stock to Hold with a $13 price target.
Capricor Therapeutics (NASDAQ: CAPR)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics (NASDAQ: CAPR) today and set a price target of $14. The company’s shares opened today at $3.10.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -14.6% and a 31.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Madrigal Pharmaceuticals Inc, and ImmunoCellular Therapeutics.

Capricor Therapeutics has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.